
|Videos|April 23, 2018
Therapeutic Approach for Metastatic Renal Cell Carcinoma
Therapeutic Approach for Metastatic Renal Cell Carcinoma
Advertisement
Case Scenario: A 73-year old female with rapidly progressing mRCC
March 2017
- A 73-year old woman with clear cell RCC, hyperlipidemia, and type 2 diabetes, which are both managed medically
- Her baseline patient and disease characteristics were:
- ECOG PS 0, KPS 90
- pT3bNxM0 (AJCC stage 3)
- 5-cm left kidney tumor mass with extension into the left renal vein
- She underwent radical nephrectomy within 1 month following diagnosis
December 2017
- The patient reported loss of appetite and weight loss
- CT imaging showed multiple liver lesions, 2 small nodules in the right lung upper lobe, and mediastinal lymphadenopathy
- Laboratory findings notable for Ca2+ 14.8 mg/dL
- PD-L1 expression, <1%
- Remarks: RCC disease progression; IMDC risk stratification, intermediate
- The patient was started on cabozantinib, 60 mg daily
- After 4 weeks on therapy she developed grade 2 diarrhea and her dose was reduced to 40 mg
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Panel Votes 10-3 In Favor of RP1 Plus Nivolumab for Advanced Melanoma
2
Improving Survival, Quality of Life, and Cost-Effectiveness for Allo-HCT
3
FDA Grants Priority Review to Subcutaneous Amivantamab for Advanced HNSCC
4
NCCN Lists Gedatolisib Regimens as Preferred Option in HR+/HER2– Metastatic Breast Cancer
5



































